459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Patel, M., Lee, J-S., De Miguel, M.J., Burns, T., Falcon Gonzalez, A., Kim, T.W., Krebs, M.G., Prenen, H., Shacham Shmueli, E., Desai, J., Lorusso, P., Sacher, A., Choi, Y., Dharia, N., Lin, M.T., Mandlekar, S., Royer-Joo, S., Schutzman, J.L., Garralda, E.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
362P Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation
Desai, J., Han, S-W., Forster, M.D., Kim, T.W., Alonso Casal, G., Shacham Shmueli, E., Bowyer, S.E., De Miguel, M.J., Falcon Gonzalez, A., Jones, R.H., Krebs, M.G., Miller, W.H., Paz-Ares, L., Lorusso, P., Sacher, A., Dharia, N., Lin, M.T., Schutzman, J.L., Shi, Z., Patel, M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
Italiano, A., Infante, J.R., Shapiro, G.I., Moore, K.N., LoRusso, P.M., Hamilton, E., Cousin, S., Toulmonde, M., Postel-Vinay, S., Tolaney, S., Blackwood, E.M., Mahrus, S., Peale, F.V., Lu, X., Moein, A., Epler, J., DuPree, K., Tagen, M., Murray, E.R., Schutzman, J.L., Lauchle, J.O., Hollebecque, A., Soria, J.-C.
Published in Annals of oncology (01.05.2018)
Published in Annals of oncology (01.05.2018)
Get full text
Journal Article
336P PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC)
Gambardella, V., Cervantes, A., Bedard, P.L., Hamilton, E.P., Italiano, A., Jhaveri, K., Juric, D., Kalinsky, K., Krop, I.E., Oliveira, M., Saura, C., Schmid, P., Turner, N., Varga, A., Liu, B.P., Chen, J.W., Aimi, J., Royer-Joo, S., Schutzman, J.L., Hutchinson, K.E.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC)
Turner, N., Jhaveri, K., Kalinsky, K., Loibl, S., Loi, S., Im, S-A., Saura, C., Schmid, P., Schutzman, J.L., Stout, T., Lei, G., Hutchinson, K.E., Thanopoulou, E., Juric, D.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article